<DOC>
	<DOCNO>NCT01613443</DOCNO>
	<brief_summary>Concentration determination anticoagulant require plasma instead whole blood , result immediately available clinician . Monitoring anticoagulant concentration along bedside method may provide alternative guide administration NOAC . The purpose investigation compare bedside coagulation assay whole blood plasma concentration new oral anticoagulant ( NOAC ) patient treat therapeutic dosis NOAC .</brief_summary>
	<brief_title>Ex-vivo Effect New Oral Anticoagulants Point-of-care Devices</brief_title>
	<detailed_description>This open-label study perform ex vivo investigation . Patients receive NOAC dabigatran rivaroxaban therapeutic dos recruit informed consent two blood sample time obtain correlation time drug intake ( two 24 hour drug intake ) . The bedside measurement perform compare directly concentration determine plasma concentration assay . These investigation perform department Angiology university hospital Frankfurt .</detailed_description>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>The indication use NOAC provide attend physician . The criterion inclusion exclusion criterion use new oral anticoagulant must meet appropriate eligibility criterion clinical guideline describe SOPs . Patients treat dabigatran 2x150mg / prevention stroke systemic embolism nonvalvular atrial fibrillation include . Moreover , patient treat rivaroxaban 20 mg / DVT prophylaxis treatment recurrent DVT PE include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Dabigatran , Rivaroxaban , Point Care-testing</keyword>
</DOC>